CliffBio
small molecule

OFEV

NINTEDANIB ESYLATE

Loss of exclusivityDecember 2029latest FDA-listed patent expiry
CompanyBoehringer Ingelheim →See this company's full patent-cliff portfolio

Drug detail

Brand nameOFEV
Active ingredientNINTEDANIB ESYLATE
StrengthEQ 150MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2014
Marketing statusRX

Listed patents

PatentExpiresType
9907756*PEDDecember 2029—
10105323*PEDDecember 2029—
9907756June 2029product
10105323June 2029product
10154990*PEDJuly 2026—
6762180*PEDApril 2026—
10154990January 2026use U-2620
6762180October 2025substance, product

Regulatory exclusivity

CodeExpires
PEDMarch 2027
ODE-261September 2026

More from Boehringer Ingelheim

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.